Roche, NewLink Genetics Sign Potential $1 Billion Plus Immunotherapy PactBy
NewLink Genetics Corporation, a biopharmaceutical company focused on discovering, developing, and commercializing immunotherapeutics to treat cancer, has formed an exclusive worldwide license agreement with
Under the terms of the agreement, NewLink will receive an upfront payment of
NewLink will retain the option for co-promotion rights for
IDO pathway inhibitors are another class of immune check point inhibitors akin to the recently developed antibodies targeting CTLA-4, PD-1, and PD-L1 that represent potential breakthrough approaches to cancer therapy. The IDO pathway regulates immune response by suppressing T-cell activation, which enables local tumor immune escape. Recent studies have demonstrated that the IDO pathway is active in many cancers, both within tumor cells as a direct defense against T-cell attack, and also within antigen presenting cells in tumor draining lymph nodes whereby this pathway promotes peripheral tolerance to tumor associated antigens (TAAs). When hijacked by developing cancers in this manner, the IDO pathway may facilitate the survival, growth, invasion, and metastasis of malignant cells whose expression of TAAs might otherwise be recognized and attacked by the immune system.
NewLink has a number of active programs directed at synthesizing inhibitors to the IDO pathway and additionally has discovered novel tryptophan-2,3-dioxygenase (TDO) specific inhibitors that are potential anti-cancer compounds which could function individually or in combination with IDO inhibition.
Source: NewLinks Genetics